Sugi Predict

Sugi Predict / Compounds / SCHEMBL15599482

SCHEMBL15599482

SCHEMBL15599482

Cc1nnc(-c2ncccn2)o1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 1/20 0.40
▸ TRPV1 Q8NER1 1/20 0.36
▸ ACHE P22303 2/20 0.35
▸ NPC1 O15118 3/20 0.34
▸ RAB9A P51151 3/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ CASP3 P42574 1/20 0.34
▸ SENP8 Q96LD8 1/20 0.34
▸ SENP7 Q9BQF6 1/20 0.34
▸ SENP6 Q9GZR1 1/20 0.34
▸ NOTUM Q6P988 2/20 0.34
▸ PDK2 Q15119 1/20 0.33
▸ CA12 O43570 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA9 Q16790 1/20 0.33
▸ POLB P06746 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ NFKB1 P19838 1/20 0.32
▸ NFKB2 Q00653 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23576598 0.77 KDM4E (0.34) BRD4NPC1RAB9ASMN1; SMN2NOTUM
SCHEMBL29816697 0.75 KDM4E (0.54) BRD4NPC1RAB9ASMN1; SMN2POLB
SCHEMBL11982529 0.75 KDM4E (0.54) BRD4NPC1RAB9ASMN1; SMN2POLB
SCHEMBL10068343 0.74 NOTUM (0.38) BRD4NPC1RAB9ASMN1; SMN2CASP3
SCHEMBL24921502 0.74 NPC1 (0.40) BRD4NPC1RAB9ASMN1; SMN2POLB
SCHEMBL24922486 0.74 LRRK2 (0.36) BRD4TRPV1NOTUMNFKB1NFKB2
SCHEMBL24922503 0.74 PCSK9 (0.44) BRD4NOTUMHPGD
SCHEMBL26766171 0.74 CYP2A6 (0.44) BRD4TRPV1ACHENPC1RAB9A
SCHEMBL26195627 0.74 BRD4 (0.49) BRD4TRPV1NPC1RAB9ASMN1; SMN2
SCHEMBL24920778 0.73 PIM1 (0.39) BRD4NPC1RAB9AAOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365592-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. 2023-11-16 — — US disclosed
US-20230365592-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. 2023-11-16 — — US disclosed
CN-114845778-A Dihydrocyclopentaisoquinoline sulfonamide derivative compound UCB生物制药有限责任公司 2022-08-02 — — CN disclosed
US-9505749-B2 Quinazolinone compounds and derivatives thereof AMGEN INC. (US) 2016-11-29 — — US disclosed
US-20150225396-A1 Quinazolinone Compounds and Derivatives Thereof AMGEN INC. 2015-08-13 — — US disclosed
WO-2014036022-A1 QUINAZOLINONE COMPOUNDS AND DERIVATIVES THEREOF AMGEN INC. (US) 2014-03-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225396-A1 Quinazolinone Compounds and Derivatives Thereof TNKS, TPI1, TNKS1BP1 BRD4 533/4885TRPV1 3789/4885ACHE 1327/4885
US-20230365592-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS PAH, KDM8, PHF8 BRD4 3460/4885TRPV1 3939/4885ACHE 4435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.